Kahn Brothers Group Inc. acquired a new position in Novartis AG (NYSE:NVS - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 13,186 shares of the company's stock, valued at approximately $2,067,000.
Other large investors have also recently modified their holdings of the company. Dearborn Partners LLC bought a new stake in shares of Novartis in the second quarter valued at approximately $5,021,000. First Bancorp Inc ME bought a new position in Novartis in the 2nd quarter worth approximately $57,000. Pinnacle West Asset Management Inc. bought a new position in Novartis in the 2nd quarter worth approximately $651,000. Somerville Kurt F purchased a new position in Novartis in the 2nd quarter valued at approximately $1,636,000. Finally, Trust Co. of Vermont bought a new stake in Novartis during the 2nd quarter valued at $7,282,000. Hedge funds and other institutional investors own 13.12% of the company's stock.
Wall Street Analyst Weigh In
Several research firms have issued reports on NVS. Citigroup restated a "buy" rating on shares of Novartis in a research report on Wednesday, July 22nd. Weiss Ratings reiterated a "buy (b)" rating on shares of Novartis in a research note on Friday, July 24th. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $141.20.
Check Out Our Latest Analysis on NVS
Novartis Price Performance
NVS stock opened at $154.54 on Friday. The firm has a 50 day moving average of $154.94 and a 200-day moving average of $153.78. The firm has a market capitalization of $294.88 billion, a P/E ratio of 23.31, a price-to-earnings-growth ratio of 2.70 and a beta of 0.45. Novartis AG has a 12 month low of $121.57 and a 12 month high of $170.46. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89.
Novartis (NYSE:NVS - Get Free Report) last posted its earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. The business had revenue of $14.95 billion for the quarter. As a group, sell-side analysts predict that Novartis AG will post 8.85 earnings per share for the current fiscal year.
Novartis Company Profile
(
Free Report)
Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.
The company's activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Novartis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.
While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
